NEW YORK, March 19 – Toronto-based proteomics company Syn X Pharma said Monday it would build the infrastructure to conduct in-house clinical trials.
The company, which recently hired a proteomics executive from Ciphergen and a business development expert from Eli Lilly, said the move signaled its efforts to begin bringing its products to market.
"This is a significant step for Syn X Pharma as we move towards commercialization of our products," Sean McNicholas, the company’s CEO, said in a statement. "By building this capability internally we will be able to shorten the time to market for all of our products, both diagnostic and therapeutic, developed using our proprietary Proteomics Discovery platform.”
That Proteomics Discovery system is used to identify protein targets that can be used to develop new drugs and antibody-based diagnostics.
The company has hired Leah Im as clinical trials project manager. Her first assignment will be to start the trial for strokepanel, a point-of-care blood test to diagnose stroke. Syn X is also in the process of developing diagnostics for diabetes, cardiovascular diseases, including heart failure and hypertension, and central nervous system diseases such as Alzheimer's.
Syn X did not comment on the amount of money it would invest to build the clinical trials capabilities. A spokesperson was not immediately available for comment.